Mesoblast (MESO) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked analysts ...

Mesoblast (MESO) has released an update. Mesoblast’s allogeneic cell therapy, Revascor, has shown promising results in ...

Mesoblast’s Revascor gets US FDA’s regenerative medicine advanced therapy designation in children with congenital heart disease: New York Friday, December 6, 2024, 18:00 Hrs [ ...

Phase 3 trial results published in European Journal of Heart Failure identify key target population for Mesoblast allogeneic cell therapyNEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited ...

Mesoblast Limited announced a key publication in the November 2024 online issue of the prestigious peer-reviewed European Journal of Heart Failure, which re ...

This identifies the target HFrEF population that is responsive to REVASCOR therapy. DREAM-HF’s lead investigator, Dr. Emerson C. Perin, MD, PhD, FACC, Medical Director at The Texas Heart ...

reducing inflammation and preventing the immune system from attacking healthy tissues, creating a favourable environment for tissue growth ("immunomodulation").

Mesoblast Ltd (ASX: MSB) shares are under pressure today despite some big news. What's going on with this share?

Earlier this year FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart disease NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE ...

Mesoblast Chief Executive Silviu Itescu said: “We appreciate FDA’s support in designating REVASCOR both RMAT and RPD status, a recognition of the potential impact of our therapy on the long ...

This identifies the target HFrEF population that is responsive to REVASCOR therapy.” ...